TeraRecon Aorta.CT vs ElucidVivo A.3
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
TeraRecon Aorta.CT focuses on automatically segmenting and labeling the aorta's anatomical landmarks from CT angiography for procedure planning. In contrast, ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability from CT angiography to aid in atherosclerosis patient stratification and treatment decisions. While both leverage CT angiography for cardiovascular care, TeraRecon addresses anatomical mapping of the aorta, whereas ElucidVivo specializes in detailed plaque characterization.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
TeraRecon Aorta.CT is designed for automatic segmentation and labeling of anatomical landmarks of the Aorta from CT Angiography scans, aiding in patient management and procedure planning for aortic conditions. ElucidVivo A.3 focuses on quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
TeraRecon Aorta.CT provides automatic 3D segmentation of the Aorta and labeling of its anatomical landmarks, outputting DICOM result files. ElucidVivo A.3 offers AI-powered quantitative analysis of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, visualizes lesion-level plaque composition, and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
TeraRecon Aorta.CT is a containerized application (e.g., Docker) deployable on standard off-the-shelf hardware or cloud platforms, and integrates with TeraRecon Intuition and Eureka Clinical AI. ElucidVivo A.3 is a software application, likely on-premise or cloud-based, that integrates with PACS/EMR systems.
TeraRecon Aorta.CT is best suited for aiding in patient management and procedure planning related to the Aorta. ElucidVivo A.3 is designed to assist physicians in stratifying patients with atherosclerosis and optimizing treatment decisions by providing detailed plaque characteristics and FFRct derivation.
TeraRecon Aorta.CT specifically processes CT Angiography with contrast DICOM images. ElucidVivo A.3 performs quantitative analysis of arterial plaque from CT angiography, with its plaque characterization validated against ground-truth histology.
TeraRecon Aorta.CT explicitly states that it does not alter original input data or provide a diagnosis. ElucidVivo A.3 assists physicians in patient stratification and optimizing treatment decisions, and its measurements are not intended to provide a diagnosis or clinical recommendations.
Both tools are FDA-cleared. ElucidVivo A.3's detailed visualization and measurement of plaque characteristics are validated against ground-truth histology, and it derives FFRct based on vessel wall vasodilative capacity.